“MC”-driven CIDeCARs proliferate, persist and eliminate tumors in preclinical studies
CHICAGO, IL, USA I May 30, 2015 I Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, announced the presentation of a poster at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) highlighting the potent anti-tumor effects of CAR T cells constructed with its novel, proprietary, dual co-stimulatory domain, “MC” (MyD88/CD40). MC is incorporated alongside Bellicum’s proprietary CaspaCIDe® safety switch in the Company’s CIDeCAR™ product candidates, including BPX-401.
The studies evaluated in vivo tumor-killing abilities of two different CIDeCARs: CD19-targeted CIDeCAR cells (BPX-401) were evaluated in a Raji lymphoma model, and Her2-targeted CIDeCAR cells were evaluated in an SK-BR-3 breast cancer model.
Study Highlights:
- MC co-stimulation resulted in increased T cell proliferation and enhanced efficacy in lymphoma and solid tumor models in vivo compared to control CAR T cells that included the more commonly utilized co-stimulatory molecule, CD28.
- The Company’s CD19-targeted CAR (BPX-401) elicited dose-dependent elevation of cytokines, analogous to cytokine release syndrome, but cytokine levels were rapidly normalized upon administration of rimiducid, without loss of tumor control.
- The percentage of BPX-401 cells eliminated upon rimiducid administration was dose-dependent across a 2-3 log range.
“We believe the development of more potent CAR T cells will be critical to success in bulky lymphomas and solid tumors,” commented Tom Farrell, Bellicum’s President and Chief Executive Officer. “These data suggest that our novel, dual co-stimulatory domain, MC, enhances anti-tumor efficacy compared to traditional CAR constructs. Furthermore, the risk of toxicity can be mitigated through our proprietary CaspaCIDe safety switch, potentially in such a way that therapeutic benefit can be maintained even when the switch is activated.”
The poster, titled “MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells,” can be accessed on the Events and Presentations page of the Company’s website.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR-T and TCR cell therapy, and dendritic cell vaccines. More information can be found at www.bellicum.com.
SOURCE: Bellicum Pharmaceuticals
Post Views: 228
“MC”-driven CIDeCARs proliferate, persist and eliminate tumors in preclinical studies
CHICAGO, IL, USA I May 30, 2015 I Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, announced the presentation of a poster at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) highlighting the potent anti-tumor effects of CAR T cells constructed with its novel, proprietary, dual co-stimulatory domain, “MC” (MyD88/CD40). MC is incorporated alongside Bellicum’s proprietary CaspaCIDe® safety switch in the Company’s CIDeCAR™ product candidates, including BPX-401.
The studies evaluated in vivo tumor-killing abilities of two different CIDeCARs: CD19-targeted CIDeCAR cells (BPX-401) were evaluated in a Raji lymphoma model, and Her2-targeted CIDeCAR cells were evaluated in an SK-BR-3 breast cancer model.
Study Highlights:
- MC co-stimulation resulted in increased T cell proliferation and enhanced efficacy in lymphoma and solid tumor models in vivo compared to control CAR T cells that included the more commonly utilized co-stimulatory molecule, CD28.
- The Company’s CD19-targeted CAR (BPX-401) elicited dose-dependent elevation of cytokines, analogous to cytokine release syndrome, but cytokine levels were rapidly normalized upon administration of rimiducid, without loss of tumor control.
- The percentage of BPX-401 cells eliminated upon rimiducid administration was dose-dependent across a 2-3 log range.
“We believe the development of more potent CAR T cells will be critical to success in bulky lymphomas and solid tumors,” commented Tom Farrell, Bellicum’s President and Chief Executive Officer. “These data suggest that our novel, dual co-stimulatory domain, MC, enhances anti-tumor efficacy compared to traditional CAR constructs. Furthermore, the risk of toxicity can be mitigated through our proprietary CaspaCIDe safety switch, potentially in such a way that therapeutic benefit can be maintained even when the switch is activated.”
The poster, titled “MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells,” can be accessed on the Events and Presentations page of the Company’s website.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR-T and TCR cell therapy, and dendritic cell vaccines. More information can be found at www.bellicum.com.
SOURCE: Bellicum Pharmaceuticals
Post Views: 228
